Cephalon distancing Provigil from Plavix
Executive Summary
Cephalon believes that its settlements with four generic manufacturers over patents for the excessive sleepiness therapy Provigil are not comparable to Bristol-Myers Squibb and Sanofi-Aventis' recently rejected settlement with Apotex over Plavix generics. When asked by "The Pink Sheet" whether FTC granted antitrust clearance to the deals, firm responds: "Our case is unrelated to the Bristol-Myers case. Cephalon is not subject to a consent decree that would require FTC approval of settlements. Similarities end at the fact that we both have made settlements with generic companies." The Provigil agreements are subject to antitrust clearance and FTC has expressed concern about the deals (1"The Pink Sheet" May 1, 2006, p. 10)...
You may also be interested in...
Brand/Generic Deals Stay In FTC’s Crosshairs As It Seeks Legal Ammunition
The Federal Trade Commission will not remain complacent as brand and generic companies accelerate the pace and expand the boundaries of settlements, Commissioner Jon Leibowitz said
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.